DE1795067A1 - Kollagenhydrolysat und -depolymerisat sowie Verfahren zu seiner Herstellung - Google Patents
Kollagenhydrolysat und -depolymerisat sowie Verfahren zu seiner HerstellungInfo
- Publication number
- DE1795067A1 DE1795067A1 DE19681795067 DE1795067A DE1795067A1 DE 1795067 A1 DE1795067 A1 DE 1795067A1 DE 19681795067 DE19681795067 DE 19681795067 DE 1795067 A DE1795067 A DE 1795067A DE 1795067 A1 DE1795067 A1 DE 1795067A1
- Authority
- DE
- Germany
- Prior art keywords
- collagen
- calcium
- content
- collagen hydrolyzate
- acidic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000008186 Collagen Human genes 0.000 title claims description 41
- 108010035532 Collagen Proteins 0.000 title claims description 41
- 229920001436 collagen Polymers 0.000 title claims description 41
- 238000000034 method Methods 0.000 title claims description 10
- 238000004519 manufacturing process Methods 0.000 title claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 18
- 239000011575 calcium Substances 0.000 claims description 18
- 229910052791 calcium Inorganic materials 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 15
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 229910019142 PO4 Inorganic materials 0.000 claims description 7
- 230000002378 acidificating effect Effects 0.000 claims description 7
- 230000015556 catabolic process Effects 0.000 claims description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 5
- 239000010452 phosphate Substances 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 3
- 150000007513 acids Chemical class 0.000 claims 2
- 230000009286 beneficial effect Effects 0.000 claims 1
- 231100000252 nontoxic Toxicity 0.000 claims 1
- 230000003000 nontoxic effect Effects 0.000 claims 1
- 239000011541 reaction mixture Substances 0.000 claims 1
- 229960005069 calcium Drugs 0.000 description 16
- 235000001014 amino acid Nutrition 0.000 description 12
- 239000000243 solution Substances 0.000 description 11
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 239000000126 substance Substances 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 229910000019 calcium carbonate Inorganic materials 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000011593 sulfur Substances 0.000 description 4
- 229910052717 sulfur Inorganic materials 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 239000000853 adhesive Substances 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 239000001506 calcium phosphate Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 2
- 239000000920 calcium hydroxide Substances 0.000 description 2
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 159000000007 calcium salts Chemical class 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-M 1,1-dioxo-1,2-benzothiazol-3-olate Chemical compound C1=CC=C2C([O-])=NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-M 0.000 description 1
- QGZKDVFQNNGYKY-AKLPVKDBSA-N Ammonia-N17 Chemical compound [17NH3] QGZKDVFQNNGYKY-AKLPVKDBSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 235000008733 Citrus aurantifolia Nutrition 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 235000004789 Rosa xanthina Nutrition 0.000 description 1
- 241000109329 Rosa xanthina Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 235000011941 Tilia x europaea Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 description 1
- 239000001527 calcium lactate Substances 0.000 description 1
- 229960002401 calcium lactate Drugs 0.000 description 1
- 235000011086 calcium lactate Nutrition 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000004571 lime Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB3994667 | 1967-08-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE1795067A1 true DE1795067A1 (de) | 1972-01-20 |
Family
ID=10412357
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19681795067 Pending DE1795067A1 (de) | 1967-08-31 | 1968-08-06 | Kollagenhydrolysat und -depolymerisat sowie Verfahren zu seiner Herstellung |
Country Status (6)
| Country | Link |
|---|---|
| BE (1) | BE718683A (OSRAM) |
| CH (1) | CH494250A (OSRAM) |
| DE (1) | DE1795067A1 (OSRAM) |
| ES (1) | ES357508A1 (OSRAM) |
| FR (1) | FR7911M (OSRAM) |
| GB (1) | GB1227534A (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2918098A1 (de) * | 1978-05-19 | 1979-11-22 | Philip Nicholas Dr Sawyer | Haemostatisches mittel, verfahren zu seiner herstellung und seine verwendung zur kontrolle doer stillung einer blutung |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2353282A1 (fr) * | 1976-06-02 | 1977-12-30 | Invap Etablissement | Application de l'elastine et de ses derives en cosmetique |
| US4390519A (en) | 1978-05-19 | 1983-06-28 | Sawyer Philip Nicholas | Bandage with hemostatic agent and methods for preparing and employing the same |
| US4344967A (en) * | 1979-08-07 | 1982-08-17 | Devro, Inc. | Film forming composition and uses thereof |
| US4285986A (en) * | 1980-01-21 | 1981-08-25 | Seton Company | Oligopeptides derived from collagen |
| JPS5767521A (en) * | 1980-09-25 | 1982-04-24 | Yamanouchi Pharmaceut Co Ltd | Agent for improving circulation blood vessel |
| GB8306935D0 (en) * | 1983-03-14 | 1983-04-20 | Isinglass Manufacturers Ltd | Treating collagen |
| CA1302880C (en) * | 1986-07-25 | 1992-06-09 | Peter Koepff | Agents for the treatment of arthroses |
| DE4125400C2 (de) * | 1991-07-31 | 2000-08-17 | Edwin Klaus | Verwendung von unlöslichem Kollagen zur Behandlung von degenerativen, nicht entzündlichen Gelenkprozessen |
| ES2141732T3 (es) * | 1993-02-02 | 2000-04-01 | Edwin Dr Klaus | Uso de colagenos para el tratamiento de procesos articulares patologicos. |
| ES2233947T3 (es) * | 1994-08-23 | 2005-06-16 | Deutsche Gelatine-Fabriken Stoess Ag | Empleo de colageno hidrolizado, de sabor neutro, y agente que lo contiene. |
| WO1996041817A1 (en) * | 1995-06-10 | 1996-12-27 | Pentapharm Ag | Collagen peptide fraction and its uses |
| JP4609807B2 (ja) * | 1996-03-28 | 2011-01-12 | 雪印乳業株式会社 | 骨強化用医薬、飲食品及び飼料 |
| JPH1112192A (ja) * | 1997-06-18 | 1999-01-19 | Zenyaku Kogyo Kk | 骨粗鬆症予防・治療剤 |
| DE19739031A1 (de) * | 1997-09-05 | 1999-03-11 | Suwelack Nachf Dr Otto | Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung |
| DE10133197A1 (de) * | 2001-07-07 | 2003-01-23 | Beiersdorf Ag | Aminosäuren enthaltende kosmetische und dermatologische Zubereitungen zur Behandlung und aktiven Prävention trockener Haut und anderer negativer Veränderungen der physiologischen Homöostase der gesunden Haut |
| DE10339180A1 (de) * | 2003-08-21 | 2005-03-24 | Deutsche Gelatine-Fabriken Stoess Ag | Kollagenhydrolysat |
| US7651531B2 (en) * | 2004-12-23 | 2010-01-26 | Council Of Scientific And Industrial Research | Bio-tanning process for leather making |
| EP1844107A1 (en) * | 2004-12-30 | 2007-10-17 | Council of Scientific & Industrial Research | Process for the preparation of bio-tanning agent |
-
1967
- 1967-08-31 GB GB1227534D patent/GB1227534A/en not_active Expired
-
1968
- 1968-07-26 BE BE718683D patent/BE718683A/xx unknown
- 1968-07-29 FR FR160976A patent/FR7911M/fr not_active Expired
- 1968-07-29 CH CH1135668A patent/CH494250A/fr not_active IP Right Cessation
- 1968-08-06 DE DE19681795067 patent/DE1795067A1/de active Pending
- 1968-08-23 ES ES357508A patent/ES357508A1/es not_active Expired
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2918098A1 (de) * | 1978-05-19 | 1979-11-22 | Philip Nicholas Dr Sawyer | Haemostatisches mittel, verfahren zu seiner herstellung und seine verwendung zur kontrolle doer stillung einer blutung |
Also Published As
| Publication number | Publication date |
|---|---|
| CH494250A (fr) | 1970-07-31 |
| FR7911M (OSRAM) | 1970-05-11 |
| BE718683A (OSRAM) | 1968-12-31 |
| GB1227534A (OSRAM) | 1971-04-07 |
| ES357508A1 (es) | 1970-03-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE1795067A1 (de) | Kollagenhydrolysat und -depolymerisat sowie Verfahren zu seiner Herstellung | |
| DE69327544T2 (de) | Mischungen zum schutz und regenierung von geweben | |
| DE3851203T2 (de) | Gebrauch von GHL-Cu Derivaten für die Herstellung eines Medikaments zur Stimulierung des Haarwachstums. | |
| EP0289512B1 (de) | Verfahren zur verbesserung der haftfähigkeit von gelen auf der schleimhaut | |
| DE69018084T2 (de) | Methoden und zusammensetzungen für heilung von knochen. | |
| EP0207956B1 (de) | Hirudin-pa und dessen derivate, verfahren zu deren herstellung und deren verwendung | |
| DE69802005T2 (de) | Kombination aus prolaminen und polaren pflanzlichen lipiden, verfahren zu deren herstellung sowie deren verwendungen | |
| DE69001535T2 (de) | Brausendes Nagelmittel. | |
| EP0136470B1 (de) | Injizierbare Lösung zur Behandlung von Entzündungen | |
| DE3031710C2 (de) | Salze von (+)-catechin, deren herstellung und verwendung sowie diese salze enthaltende pharmazeutische zubereitungen. | |
| DE69116184T2 (de) | Topisch anwendbare Zusammensetzungen auf der Basis von hoch molekularer Hyaluronsäure zur Behandlung von Entzündungen der Mundhöhle, zu deren Hygiene und kosmetischer Behandlung | |
| EP0874618B1 (de) | Präparat zur verbesserung des haarwuchses, der hautstruktur und/oder der nagelregeneration | |
| DE3205504C2 (de) | Äußerlich anwendbares, Ibuprofen enthaltendes Arzneimittel | |
| DE68912195T2 (de) | Verwendung von Pyrrolicloncarbonsäurealkylestern zur Herstellung eines Arzneimittels zur Behandlung von Ichtyosis. | |
| DE3438455A1 (de) | L-lysin- und l-histidinpyruvat | |
| DE19538687A1 (de) | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon | |
| DE4101122A1 (de) | Kosmetisches oder pharmazeutisches mittel | |
| DE2515001C2 (de) | Prostaglandin enthaltende gefriergetrocknete Pulver | |
| DE3203310A1 (de) | Pharmazeutische zusammensetzung zur behandlung von erkrankungen der mundhoehle | |
| DE102004028805A1 (de) | Mittel zur Förderung der Collagenbildung | |
| EP0700294B1 (de) | Injektionslösung für die intramuskuläre und subkutane verabreichung an tiere | |
| DE3612232A1 (de) | Verwendung von menschlichem urogastron zur foerderung der heilung von knochen und/oder sehnen | |
| DE2364704C2 (de) | Ca-Doppelsalz des Lysins und der Chlorwasserstoffsäure und dessen pharmakologisch verträgliche Säureadditionssalze, Verfahren zu deren Herstellung und diese Säureadditionssalze enthaltende Arzneimittel | |
| EP0610655B1 (de) | Arzneimittel mit einem Gehalt an Dexpanthenol zur topischen Anwendung | |
| DE68901852T2 (de) | Primycin-loesungen. |